Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Tolerability of S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM)

NCT04141670 is registered in ClinicalTrials.gov with RyCarma Therapeutics, Inc. as lead sponsor.

NCT NCT04141670
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04141670 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Tolerability of S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM)
Lead sponsor
RyCarma Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 25, 2020
Completion date
July 30, 2023
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ryr-1 myopathy